Investing.com - Pardes Biosciences (NASDAQ: PRDS) reported first quarter EPS of $-0.300, $0.10 better than the analyst estimate of $-0.403. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Pardes Biosciences's stock price closed at $1.900. It is up 0% in the last 3 months and down -73.050% in the last 12 months.
Pardes Biosciences saw positive EPS revisions and negative EPS revisions in the last 90 days. See Pardes Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Pardes Biosciences's Financial Health score is "weak performance".
Check out Pardes Biosciences's recent earnings performance, and Pardes Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar